Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -7.66% is 94% above its 5-year average of -133.28%, near the high end of its 5-year range (-759.60%–94.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 59.94% above its 12-month average of -19.12%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -7.66%.
RETURN ON EQUITY (ROE)
-7.66%
RETURN ON EQUITY (ROE) AVG TTM
-19.12%
RETURN ON EQUITY (ROE) AVG 3Y
9.25%
RETURN ON EQUITY (ROE) AVG 5Y
-133.28%
RETURN ON EQUITY (ROE) AVG 10Y
-61.26%
RETURN ON EQUITY (ROE) AVG 15Y
-67.08%
RETURN ON EQUITY (ROE) AVG 20Y
-84.42%
CURRENT VS TTM AVG
+59.94%
CURRENT VS 3Y AVG
-182.80%
CURRENT VS 5Y AVG
+94.25%
CURRENT VS 10Y AVG
+87.50%
CURRENT VS 15Y AVG
+88.58%
CURRENT VS 20Y AVG
+90.93%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+81.77%
vs the sector median at left
Fennec Pharmaceuticals Inc.
Market Cap
$359.53M
Return on Equity (ROE)
-7.66%
TTM Avg
-19.12%
3Y Avg
9.25%
5Y Avg
-133.28%
Market Cap
$361.64M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$355.43M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$355.36M
Return on Equity (ROE)
10.07%
TTM Avg
9.56%
3Y Avg
8.63%
5Y Avg
13.79%
Market Cap
$353.88M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
Market Cap
$353.00M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$352.67M
Return on Equity (ROE)
N/A
TTM Avg
187.63%
3Y Avg
25.60%
5Y Avg
-9.96%
Market Cap
$349.70M
Return on Equity (ROE)
-200.64%
TTM Avg
-134.16%
3Y Avg
-101.12%
5Y Avg
-54.69%
Market Cap
$369.50M
Return on Equity (ROE)
-54.29%
TTM Avg
-32.16%
3Y Avg
-17.89%
5Y Avg
-29.83%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | $359.53M | -7.66% | -19.12% | 9.25% | -133.28% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -26.14% | -53.80% | -12.25% | 19.21% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 10.07% | 9.56% | 8.63% | 13.79% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -62.56% | -108.31% | -79.06% | -57.33% |
| Embecta Corp. (EMBC)vs › | $353.00M | N/A | -12.63% | -14.73% | 14.28% |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | 187.63% | 25.60% | -9.96% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -200.64% | -134.16% | -101.12% | -54.69% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | -54.29% | -32.16% | -17.89% | -29.83% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | -1229.58% | 464.26% | -581.37% | -581.37% |
ROE
-7.7%
ROA
-4.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -7.66% |
| 2026-03-31 | -22.23% |
| 2025-12-31 | -27.46% |
| 2024-03-31 | 94.36% |
| 2022-09-30 | -759.60% |
| 2022-06-30 | -203.49% |
| 2022-03-31 | -130.22% |
| 2021-12-31 | -109.98% |
| 2021-09-30 | -84.98% |
| 2021-06-30 | -81.56% |
| 2021-03-31 | -76.27% |
| 2020-12-31 | -62.29% |
| 2020-09-30 | -59.26% |
| 2020-06-30 | -39.00% |
| 2020-03-31 | -165.17% |
| 2019-12-31 | -107.58% |
| 2019-09-30 | -80.98% |
| 2019-06-30 | -79.44% |
| 2019-03-31 | -56.99% |
| 2018-12-31 | -46.39% |
| 2018-09-30 | -40.22% |
| 2018-06-30 | -35.39% |
| 2018-03-31 | -30.43% |
| 2017-12-31 | -26.33% |
| 2017-09-30 | -66.60% |
| 2017-06-30 | -41.83% |
| 2017-03-31 | -110.98% |
| 2016-12-31 | -78.12% |
| 2016-09-30 | -51.80% |
| 2016-06-30 | -38.84% |
| 2016-03-31 | -516.87% |
| 2015-12-31 | -120.26% |
| 2015-09-30 | 124.53% |
| 2015-06-30 | 159.35% |
| 2015-03-31 | 144.67% |
| 2014-12-31 | -354.98% |
| 2012-09-30 | 378.35% |
| 2012-06-30 | 121.17% |
| 2012-03-31 | 132.10% |
| 2010-09-30 | -64.42% |
| 2009-12-31 | -741.87% |
| 2008-12-31 | -448.25% |
| 2008-09-30 | -273.24% |
| 2008-06-30 | -170.69% |
| 2008-03-31 | -122.51% |
| 2007-12-31 | -94.41% |
| 2007-09-30 | -100.65% |
| 2007-06-30 | -93.38% |
| 2007-03-31 | -91.11% |
| 2006-12-31 | -238.21% |
| 2006-09-30 | -135.96% |
| 2006-06-30 | -99.33% |
| 2006-03-31 | -115.74% |
| 2005-12-31 | -95.95% |
| 2005-09-30 | -59.27% |
| 2005-06-30 | -63.26% |
| 2005-03-31 | -46.60% |
| 2004-12-31 | -26.47% |
| 2004-09-30 | -30.95% |
| 2004-06-30 | -26.45% |
| 2004-03-31 | -29.82% |
| 2003-12-31 | -24.61% |
| 2003-09-30 | -47.05% |
| 2003-06-30 | -39.06% |
